for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-VBL First-In-Class Mospd2 Antibodies Show Potential For Treatment For Cns Inflammation

May 4 (Reuters) - Vascular Biogenics Ltd:

* VBL FIRST-IN-CLASS MOSPD2 ANTIBODIES SHOW POTENTIAL FOR TREATMENT FOR CNS INFLAMMATION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up